{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:29:31Z","timestamp":1740133771942,"version":"3.37.3"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"1143","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1136\/postgradmedj-2020-137491","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T21:16:15Z","timestamp":1584738975000},"page":"51-52","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history"],"prefix":"10.1093","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-2730","authenticated-orcid":false,"given":"Miguel Fernando","family":"Garc\u00eda-Gil","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venerology, Lozano Blesa University Clinical Hospital , Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Lezcano Biosca","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Lozano Blesa University Clinical Hospital , Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Garc\u00eda Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Lozano Blesa University Clinical Hospital , Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Monte Serrano","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Lozano Blesa University Clinical Hospital , Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Aldea Manrique","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Lozano Blesa University Clinical Hospital , Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"2023041706573016100_","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"2023041706573016100_","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes","volume":"42","author":"Douros","year":"2019","journal-title":"Diabetes Care"},{"key":"2023041706573016100_","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-Induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023041706573016100_","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023041706573016100_","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2023041706573016100_","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2023041706573016100_","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","article-title":"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study","volume":"79","author":"Varpuluoma","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/97\/1143\/51\/49932427\/postgradmedj-97-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/97\/1143\/51\/49932427\/postgradmedj-97-51.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:52:35Z","timestamp":1695941555000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/97\/1143\/51\/6969551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":7,"journal-issue":{"issue":"1143","published-online":{"date-parts":[[2020,3,20]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2020-137491","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"type":"electronic","value":"1469-0756"},{"type":"print","value":"0032-5473"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,3,20]]}}}